argenx SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ARGXargenx SE 2.43%373.330.0%$115.77m
ICLRICON plc -1.05%216.802.8%$111.55m
VRXValeant Pharmaceuticals International, Inc. -4.65%8.4214.1%$49.54m
RVMDRevolution Medicines, Inc. 2.86%18.000.0%$17.86m
AMRNAmarin Corp. Plc -0.81%1.841.5%$8.41m
EVOKEvoke Pharma, Inc. 1.64%3.1039.7%$8.15m
USNAUSANA Health Sciences, Inc. -0.58%72.484.2%$5.42m
BGXXBright Green Corp. -3.59%2.420.0%$4.30m
ANIKAnika Therapeutics, Inc. 0.82%22.379.8%$3.30m
ATOSAtossa Therapeutics, Inc. 1.30%1.170.2%$2.67m
SMFLSmart for Life, Inc. 4.20%0.660.0%$2.12m
CDXCChromadex Corp. -2.79%1.742.7%$1.55m
IBIOiBio, Inc. -1.28%0.280.2%$1.18m
NATRNature's Sunshine Products, Inc. -3.69%10.570.4%$0.85m
FLGCFlora Growth Corp. -3.28%0.670.0%$0.83m

Company Profile

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.